102023 805 PM US Food and Drug Administration Approves BioMarins VOXZOGO vosoritide for Children Under 5 Years with Achondroplasia  Oct 20  httpsinvestorsbiomarincom20231020USFoodandDrugAdministrationApprovesBioMarinsVOXZOGORvosoritideforChildrenUnder5Yearswith 111Clinical Trials Contact Us Careers US Food and Drug Administration Approves BioMarins VOXZOGO vosoritide for Children Under 5 Years with Achondroplasia       Oct 20 2023 Expanded Indication in the US Now Includes Children of all ages with Achondroplasia SAN RAFAEL Calif Oct 20 2023 PRNewswire  BioMarin Pharmaceutical Inc Nasdaq BMRN a global biotechnology company dedicated to transforming lives through genetic discovery today announced that the US Food and Drug Administration FDA has approved the supplemental New Drug Application sNDA for VOXZOGO vosoritide to increase linear growth in pediatric patients with achondroplasia with open epiphyses growth plates